Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6073795 | 0.85 | ALDH1A1 (0.46) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6073524 | 0.81 | MEN1 (0.34) | ALDH1A1KDM4EMEN1KMT2AGAA | |
| SCHEMBL24885682 | 0.72 | ALDH1A1 (0.38) | LMNAALDH1A1MEN1KMT2ACYP2C19 | |
| SCHEMBL10969853 | 0.72 | LMNA (0.68) | LMNAALDH1A1KDM4EGAAMAPT | |
| SCHEMBL6074248 | 0.71 | MEN1 (0.43) | ALDH1A1MEN1KMT2AGAAMAPT | |
| SCHEMBL6605614 | 0.69 | ALDH1A1 (0.45) | LMNAALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL3431542 | 0.69 | LMNA (0.69) | LMNAALDH1A1KDM4EGAAMAPT | |
| SCHEMBL6073663 | 0.68 | CYP11B1 (0.51) | LMNAALDH1A1KDM4ECYP3A4POLB | |
| SCHEMBL16323439 | 0.67 | KMT2A (0.40) | LMNAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL18901650 | 0.66 | ALDH1A1 (0.67) | LMNAALDH1A1KDM4ECYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119207-B2 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | LMNA 3704/4885ALDH1A1 732/4885KDM4E 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.